Hosted by Dave Dixon, PharmD, CLS, FNLA, this episode features an in-depth discussion with three key authors of the NLA’s new statement providing updated guidance on diagnosis, management, and treatment of FH. Together, they review the most important updates in the new guidance, including recommendations for earlier identification, the role of genetic testing and cascade screening, updated LDL-cholesterol treatment targets, and the integration of newer lipid-lowering therapies. The conversation also addresses practical considerations for managing FH across the lifespan, from pediatric care to special populations, with a focus on translating evidence-based recommendations into real-world clinical practice.

You can watch the video version of this podcast HERE.

You can read the official NLA consensus statement published open-access in the Journal of Clinical Lipidology HERE.

Podcast listeners can claim credit for listening to the podcast HERE.
This podcast has been approved for AMA PRA Category 1 Credit™. This activity is eligible for ACPE, ANCC, and CDR credit.

Dr. Peter Jones welcomes Dr. Nihar Desai for a forward-looking discussion on the future of cardiovascular prevention. From implementation science to performance measurement, this episode challenges traditional approaches and explores how innovation, systems thinking, and accountability can reshape how we achieve lasting cardiovascular health.

Guest:

Nihar R. Desai, MD, MPH

Associate Professor of Medicine

Yale School of Medicine

Vice Chief, Section of Cardiovascular Medicine

Yale New Haven Health System

New Haven, CT

Watch the Video

In this episode of Lipid Insights, host Dr. Peter Jones is joined by Dr. Harold Bays for a practical, clinician-focused discussion of the ATTAIN Study and what it means for everyday lipid management. Together, they walk through the key questions clinicians ask when new evidence emerges: what the study set out to evaluate, how to interpret the findings in context, and where the results may (or may not) shift decision-making at the point of care.

Dr. Bays brings a real-world lens to the conversation—highlighting how study design, patient selection, endpoints, and background therapy can influence how we apply data in practice. The episode emphasizes translating evidence into action, from identifying the right patients to aligning therapeutic strategy with risk, goals, and adherence realities. Whether you’re looking to sharpen your interpretation of clinical trial data or refine your approach to lipid-related risk reduction, this discussion offers clear takeaways you can use immediately.

YouTube Link:

https://youtu.be/s65WHd1WjII

Join host Peter Jones, MD, MNLA for a conversation on the evolving landscape of metabolic health in youth. In this episode, Dr. Jones is joined by two leading pediatric experts—Don Wilson, MD, FNLA and Amy Shah, MD, FNLA—to explore practical strategies and emerging research on managing lipids and metabolic syndrome in younger populations.

The discussion highlights key findings from their recently published special issue in the Journal of Clinical Lipidology, offering listeners evidence-based insights and clinical pearls to improve outcomes in pediatric and adolescent care. Whether you’re a clinician, researcher, or simply passionate about preventive cardiometabolic health, this episode delivers expert perspectives you won’t want to miss.

Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic Disease

Hosted by Dr. Underberg, the Rewriting the Risk Equation: The Expanding Role of Lp(a) in Atherosclerotic Disease podcast is designed to equip clinicians with the latest evidence on Lp(a) biology, screening strategies, and current and emerging therapeutic options. Along with Drs. Soffer, Kulkarni and Wilkinson, they will explore the integration of Lp(a) assessment into routine practice, implications for high-risk populations including those with familial hypercholesterolemia (FH), and strategies to mitigate cardiovascular risk until targeted therapies become available. 

Podcast Listeners can claim credit for this program by Clicking Here

You can watch a video version of this podcast by Clicking Here

Can genetic scores unlock better outcomes for patients with FH? This special Snippet from our Lipid Insights podcast series dives into the award-winning abstract from #NLASessions 2025, exploring how polygenic risk scores for coronary artery disease may transform ASCVD prediction and management. Tune in and see what’s next in lipid science.

Guest Host
Daniel E. Soffer, MD, MNLA
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA

Guest
Alexis Baass, MD, MSc, FNLA Alexis Baass, MD, MSc, FNLA
Director of the Lipids
Nutrition and Cardiovascular Prevention Clinic
Montreal Clinical Research Institute
Montreal, QC, Canada

Click here to see the video version of this episode

In this episode of Lipid Insights, Dr. Peter Jones and guest Dr. Kevin Maki explore whether beef deserves its long-standing reputation as a driver of cardiovascular disease. Drawing on a recent systematic review and meta-analysis, they examine beef’s impact on cholesterol, blood pressure, and other key CVD risk factors—providing fresh perspective for clinicians navigating dietary guidance.

This podcast has been approved for AMA PRA Category 1 Credit™. This activity is eligible for ACPE, ANCC, and CDR credit. To read full accreditation information and claim credit, CLICK HERE. 

In this short episode, guest host Dr. Dan Soffer chats with Dr. Joshua Hyman, the Young Investigator Award winner at #NLASessions 2025. Dr. Hyman gives a quick overview of his award-winning abstract and shares insights from his work in advancing lipid research.

Hosted by Dr. Dan Soffer, this conversation brings NLA President Dr. Willard and Beth Jackson together to unpack the Association’s guidance, “LDL Cholesterol Management Simplified in Adults – Lower for Longer is Better.” The trio turns a big message into practical moves: why lifetime LDL exposure matters, who needs more aggressive targets, and how to streamline therapy choices from high-intensity statins to add-ons (ezetimibe, PCSK9-directed options) when goals aren’t met. They share real-world tactics on adherence, stepwise intensification, shared decision-making, and navigating special populations—all in a clear, clinic-ready format.

Read the featured article HERE

Watch this video on YouTube HERE

Guest Host
Daniel E. Soffer, MD, MNLA
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA

Kaye-Eileen Willard, MD, FNLA
Medical Director Lipid Clinic
Physician Advisor, Ascension SE Wisconsin
Chief of Staff Ascension All Saints
Chair Joint Chiefs of Staff Ascension SE Wisconsin
Racine, WI

Beth Jackson, MSN, ACNS-BC, CLS, FNLA
Prevention Lipid Clinic
App Manager
Baylor Scott and White
Division of Cardiology 
Temple, TX

In this episode, Alan Brown, MD, MHA, MNLA sits down with Rebecca Juliano, PhD, MPhil, MA to discuss a first-in-human study of an investigational ANGPTL4 inhibitory antibody. The conversation explores how this novel therapeutic approach safely and effectively reduces plasma triglycerides and remnant cholesterol—key drivers of residual cardiovascular risk. Listeners will gain insight into the mechanism of action, clinical significance, and potential role of ANGPTL4 inhibition in the evolving landscape of lipid management.

View this Episode on YouTube HERE